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Objective: To investigate whether phosphorylated tau protein
(tau-pT181) is increased in variant Creutzfeldt–Jakob
disease (vCJD) and if the tau-pT181/tau protein ratio is
useful for distinguishing between patients with and without
CJD.
Methods: CSF tau protein and tau-pT181 were measured in
50 patients with sporadic CJD (sCJD), 51 patients with vCJD,
46 sCJD controls, and 37 vCJD controls, using Innotest hTau
and Innotest P-Thr181, Innogenetics.
Results: Concentrations of CSF tau protein were increased in
sCJD (5120 v 367 pg/ml in controls, p,0.001) and vCJD
(952 v 106 pg/ml, p,0.001); tau-pT181 was also raised in
sCJD (61 v 35 pg/ml in controls, p = 0.002) and vCJD (114 v
33 pg/ml, p,0.001). Median concentrations of tau-pT181
were higher in vCJD than in sCJD (p,0.001). The tau-
pT181/tau protein ratio was lower than in controls in both
sCJD (12 v 128 (p,0.001)) and vCJD (119 v 279
(p,0.001)). Mean tau-pT181/tau protein ratio was 10-fold
higher in vCJD than in sCJD. Raised CSF tau protein had the
highest efficiency for distinguishing sCJD and vCJD from
controls.
Conclusions: CSF tau-pT181 concentrations are raised in
vCJD and are higher than in sCJD. Measurement of CSF tau-
pT181/tau protein ratio does not improve the diagnostic
efficiency of CSF tau protein alone for either vCJD or
sCJD. The higher concentration of CSF tau-pT181 found
in vCJD suggests that unexplained pathogenic factors
influence the phosphorylation of tau protein in vCJD
patients.
T
au protein is a microtubule associated protein found in
high concentrations in the axons of the central nervous
system and is involved in maintaining axonal structure
and integrity.1 It is normally phosphorylated at six to eight
sites, but it can become hyperphosphorylated in various
neurodegenerative conditions, such as Alzheimer’s disease.2
Raised levels of tau protein and phosphorylated tau have
been found in sporadic Creutzfeldt–Jakob disease (sCJD)3–6
and a recent study has suggested that the ratio of tau protein
to tau phosphorylated at threonine-181 (tau-pT181) can
distinguish sCJD from other forms of dementia.5 Raised levels
of cerebrospinal fluid (CSF) tau protein have also been found
in variant Creutzfeldt–Jakob disease (vCJD) and have been
shown to have the greatest diagnostic accuracy of all the CSF
proteins investigated for this condition.7 In this study we
investigated whether measurement of tau-pT181 and the tau-
pT181/tau protein ratio is better than CSF tau protein alone
for the diagnosis of vCJD, and have compared the results
with those found in sCJD.
METHODS
Patients
CSF samples from patients referred to the National CJD
Surveillance Unit (NCJDSU) were analysed for tau protein
and tau-pT181. The methodology of the NCJDSU has been
described elsewhere.8 All patients or their medical notes, or
both, were examined by the NCJDSU. Consecutive patients
were selected according to the volume of CSF available for
analysis. CSF was analysed from the following patients: 51
patients with neuropathologically proven or clinically prob-
able vCJD,8 9 37 vCJD control patients, 50 patients with
neuropathologically proven or clinically probable sCJD,10 and
46 sCJD control patients. Thirty two patients had neuro-
pathologically confirmed vCJD (21 male, 11 female; age
range 16 to 54 years (mean 30) at notification) and 19
patients had probable vCJD (eight male, 11 female; age range
18 to 50 years (mean 29) at notification). Thirty seven
patients had neuropathologically confirmed sCJD (17 male,
20 female; age range 50 to 81 years (mean 63) at notification)
and 13 had probable sCJD (six male, seven female; age range
44 to 77 years (mean 66) at notification).
The sCJD and vCJD control groups consisted of patients
who were initially suspected of having sCJD and vCJD,
respectively, and in whom an alternative diagnosis was
made. Of the 37 vCJD control patients (16 male, 21 female;
age range 14 to 79 years (mean 31) at notification),
neuropathological examination was carried out on seven
cases. The diagnoses in six of these were paraneoplastic
syndrome (2), Huntington’s chorea (1), multiple sclerosis
(1), subacute sclerosing panencephalitis (1), and viral
encephalopathy (1). In the remaining case there was no
definite neuropathologically confirmed diagnosis on brain
biopsy, but no evidence of vCJD. The diagnosis of vCJD was
excluded in the remaining 30 vCJD control patients for
reasons that included complete or partial recovery (10), or an
alternative diagnosis made on clinical grounds, or investiga-
tions suggestive of an alternative diagnosis (20). The
diagnoses in these 20 cases were psychiatric disorders (7),
non-CJD dementia of an unknown cause (5), encephalitis
(4), Alzheimer’s disease (1), cerebrovascular disease (1),
epilepsy (1), and mitochondrial cytopathy (1).
Of the 46 sCJD control patients (18 male, 28 female; age
range 41 to 84 (mean 68) at notification), 20 had a
postmortem neuropathological examination. The diagnoses
in 17 of these cases were: Alzheimer’s disease (6), Lewy body
dementia (2), cerebrovascular disease (2), angiotrophic
lymphoma (1), carcinomatosis of leptomeninges (1), cerebral
vasculitis (1), ischaemic encephalopathy (1), multifocal
demyelination (1), multifocal lymphoma (1), and viral
Abbreviations: tau-pT181, tau protein phosphorylated at threonine-
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encephalitis (1). In the remaining three cases, there was no
definite neuropathologically confirmed diagnosis on brain
biopsy, but no evidence of sCJD. The diagnosis of sCJD was
excluded in the final 26 patients for reasons that include
partial recovery (5), or an alternative diagnosis made on
clinical grounds, or investigations suggestive of an alternative
diagnosis (21). The diagnoses in these 21 cases were: Lewy
body dementia (3), non-CJD dementia of an unknown cause
(3), frontal lobe dementia (2), Alzheimer’s disease (2),
Hashimoto’s encephalitis (2), paraneoplastic syndrome (2),
central pontine myelinolysis (1), cerebrovascular ischaemia
(1), granulomatous disease (1), Huntington’s disease (1),
paraneoplastic encephalitis (1), vascular dementia (1), and
vasculitis (1).
CSF analysis
Aliquots of all CSF samples were taken and stored at 280 C˚
before analysis. CSF tau protein and tau-pT181 were
measured using enzyme immunoassays (Innotest hTAU-Ag
or Innotest P-Thr181, Innogenetics, Ghent, Belgium). The
measurement of both tau protein and tau-pT181 were made
according to the manufacturer’s recommendations. The tau-
pT181/tau protein ratio was expressed as a ratio of the
concentrations multiplied by a factor of 1000.
Statistics
Non-parametric tests (Mann–Whitney U test, Kruskall–
Wallis test, Spearman correlation) were used, as neither tau
protein nor tau-pT181 was normally distributed.
RESULTS
CSF concentrations of tau protein, tau-pT181, and the tau-
pT181/tau protein ratio for both sCJD and vCJD and the
relevant control groups are shown in fig 1. The diagnostic
value of each of these markers is shown in table 1.
Efficiency is defined as the number of true positive and
true negative values expressed as a percentage of the total
number of patients investigated. Cut off values for tau-pT181
and the tau-pT181/tau protein ratio were calculated using
receiver operator curves; the cut off value used for tau protein
was that previously described.4
The mean concentration of CSF tau-pT181 was signifi-
cantly raised in vCJD patients compared with vCJD control
patients (114 v 33 pg/ml, p,0.001) and sCJD patients (114 v
61 pg/ml, p,0.001). The mean concentration of tau-pT181
was raised in sCJD patients compared with sCJD controls (61
v 35 pg/ml, p = 0.002). There was no evidence of an effect of
age, sex, or disease duration on the tau-pT181 protein
concentration in either sCJD or vCJD.
The mean concentration of CSF tau protein was signifi-
cantly raised in vCJD and sCJD when compared with the
appropriate control groups (952 v 106 pg/ml, p,0.001; and
5120 v 367 pg/ml, p,0.001, respectively). CSF tau protein
had the greatest efficiency for discriminating between both
vCJD and sCJD from their respective control patients
(table 1). There was a strong correlation between tau protein
and tau-pT181 protein in vCJD patients and vCJD controls
(Spearman’s test, p,0.001), no evidence of a correlation in
sCJD patients (p = 0.3), and slight evidence of a correlation
in sCJD controls (p = 0.049).
The tau-pT181/tau protein ratios for vCJD and sCJD were
significantly lower than in the appropriate control groups
(119 v 279, p,0.001; 12 v 128, p,0.001, respectively), but
this ratio did not improve the diagnostic efficiency of CSF tau
protein alone (table 1).
DISCUSSION
Patients with vCJD and sCJD had significantly raised
concentrations of tau protein and tau-pT181 compared with
control patients. Interestingly the concentration of CSF tau-
pT181 was higher in vCJD patients than in sCJD or either
group of control patients. As there was no correlation
between tau-pT181 concentration and age or disease duration
in either vCJD or sCJD, the difference in mean concentration
between these two forms of CJD is unlikely to be explained by
the younger age or the longer clinical course in vCJD patients.
The fact that the mean concentration of tau-pT181 is
higher in vCJD than in sCJD, in contrast to tau protein levels
where the reverse is true, suggests that the factors governing
the release or metabolism of tau protein and tau-pT181 are
different in these two forms of CJD. It is thought that tau
protein is released into the CSF as a result of neuronal
damage or death and that the magnitude of the concentra-
tions reflects the extent and rate of this process. As sCJD has
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Figure 1 Combined scatter and box plots of CSF tau-pT181
concentrations, CSF tau protein concentrations, and CSF tau-pT181/tau
protein ratio61000. Variant CJD (vCJD) cases are represented by filled
circles, vCJD controls by empty circles, sporadic sCJD cases (sCJD) by
filled squares, and sCJD controls by filled triangles. The scatterplots
represent the individual values from which the boxes are derived.
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a more rapid clinical course than vCJD this would explain the
higher mean concentrations of CSF tau protein in sCJD than
in vCJD. The higher mean concentrations of CSF tau-pT181
in vCJD than in sCJD or in the control patients suggests that
there are factors as yet unexplained that influence the
phosphorylation of tau protein in vCJD patients. CSF tau-
pT181 concentrations are increased in Alzheimer’s disease, a
condition associated with neurofibrillary tangles (NFTs), but
there is no neuropathological evidence that vCJD patients
have NFTs or any other tau inclusion bodies.11 At present, it is
unclear whether this increase in tau-pT181 results from
increased phosphorylation of tau protein or from a reduction
or resistance to de-phosphorylation.
The mean tau-pT181/tau protein ratio in vCJD was
significantly lower than in the relevant control group but
was not as efficient as the CSF tau protein alone in
discriminating between these two groups of patients.
Interestingly the tau-pT181/tau protein ratio is higher in
vCJD than in sCJD and reflects the differences in magnitude
of the two proteins in the two forms of CJD.
Conclusions
CSF tau-pT181 is the only surrogate marker investigated so
far that is significantly raised in vCJD when compared with
sCJD and controls. Despite this, measurement of CSF tau-
pT181 or calculation of the tau-pT181/tau protein ratio does
not improve the diagnostic accuracy of tau protein alone.
Whether raised CSF tau-pT181 levels may be of diagnostic
value in distinguishing between vCJD and sCJD in a clinical
setting will require further investigation. Interestingly the
observation that vCJD patients have higher concentrations of
CSF tau-pT181 than patients with sCJD suggests that the
pathogenic factors governing the phosphorylation of tau
protein in these two conditions are different.
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tau-pT181/tau protein ratio in sporadic and variant CJD
SCJD:
Tau protein
>1300 pg/ml
Tau-pT181
>50 pg/ml
Tau-pT181/tau protein ratio
(60
Sensitivity (%) 84 60 88
Specificity (%) 91 61 74
Efficiency (%) 88 60 81
VCJD:
Tau protein
>400 pg/ml
Tau-pT181
>70 pg/ml
Tau-pT181/tau protein ratio
(200
Sensitivity (%) 90 84 86
Specificity (%) 89 86 78
Efficiency (%) 90 85 83
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